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Original Article
Background: Impairments in psychosocial status and cognition relate to 
poor clinical outcomes in patients with atrial fibrillation (AF). However, 
how often these conditions co-occur and associations between burden of 
psychosocial and cognitive impairment and quality of life (QoL) have not 
been systematically examined in patients with AF.
Methods: A total of 218 patients with symptomatic AF were enrolled in a 
prospective study of AF and psychosocial factors between May 2013 and 
October 2014 at the University of Massachusetts Medical Center. Cognitive 
function, depression, and anxiety were assessed at baseline and AF-specific 
QoL was assessed 6 months after enrollment using validated instruments. 
Demographic and clinical information were obtained from a structured 
interview and medical record review.
Results: The mean age of the study participants was 63.5 ± 10.2 years, 35% 
were male, and 81% had paroxysmal AF. Prevalences of impairment in 1, 2, 
and 3 psychosocial/cognitive domains (eg, depression, anxiety, or cognition) 
were 75 (34.4%), 51 (23.4%), and 16 (7.3%), respectively. Patients with 
co-occurring psychosocial/cognitive impairments (eg, >1 domain) were older, 
more likely to smoke, had less education, and were more likely to have heart 
failure (all P < 0.05). Compared with participants with no psychosocial/cognitive 
impairments, AF-specific QoL at 6 months was significantly poorer among 
participants with baseline impairment in 2 (B = −13.6, 95% CI: −21.7 to −5.4) or 
3 (B = −15.1, 95% CI: −28.0 to −2.2) psychosocial/cognitive domains.
Conclusion: Depression, anxiety, and impaired cognition were common in our 
cohort of patients with symptomatic AF and often co-occurred. Higher burden of 
psychosocial/cognitive impairment was associated with poorer AF-specific QoL.
Key Words: atrial fibrillation, psychosocial impairment, cognitive 
impairment, multimorbidity, quality of life
(Crit Pathways in Cardiol 2017;16: 71–75)
Atrial fibrillation (AF) is the most common sustained heart rhythm abnormality, affecting approximately 3–6 million US adults, 
including almost 1 in 20 people over age 60.1,2 Owing to the aging 
of the US population, the number of people diagnosed with AF is 
expected to more than double by the year 2050.1,3 The increasing 
prevalence of AF has significant personal, clinical, and socioeco-
nomic implications,4 in part due to the fact that patients with AF 
often also have anxiety, depression, and cognitive impairment (CI) or 
dementia, even in the absence of ischemic stroke.5,6
Impairments in mood or cognition exert powerful and nega-
tive impacts on the prognosis of AF patients.6–9 Specifically, depres-
sion and anxiety are associated with poorer AF outcomes, including 
higher AF recurrence rates, higher mortality rates, worse symptom 
severity, and greater health care utilization.6–9 Patients with AF who 
are affected by CI have poorer anticoagulation adherence, more fre-
quent adverse cardiovascular events, and show greater functional 
impairment compared with nonimpaired AF patients.10
Although individually harmful, psychosocial and/or CIs may 
in fact confer even poorer outcomes when they occur together, and 
evidence suggests that these impairments frequently cluster.11 For 
example, anxiety and depression often co-occur in the general popu-
lation,11 and their combined presence negatively impacts important 
health outcomes, including somatic symptomatology, treatment 
response, and suicidality.11,12 Studies also show that patients with 
even mild CI are vulnerable to mood disorders, including depres-
sion.13 Data also show that psychosocial and CIs cluster in patients 
with coronary artery disease, in whom anxiety and depression occur 
together commonly,14–16 and in whom the combination of anxiety and 
depression confers a higher risk for worse cardiovascular outcomes 
than either anxiety or depression alone.15,16
Despite work highlighting the profound impact of depression, 
anxiety, or CI individually on the long-term prognosis of patients 
with AF and data showing clustering of psychosocial and cogni-
tive comorbidities in patients with other forms of cardiovascular 
disease,6–9,14,16 we know little about patterns of co-occurrence in AF 
patients, their joint influence on AF-related quality of life (QoL), 
or patient factors associated with a greater burden of psychosocial 
and CIs. To address these knowledge gaps, we conducted the present 
analysis using data from InRhythm, a prospective study of psychoso-
cial and cognitive factors in AF.
METHODS
Study Sample
The InRhythm study is a prospective study of AF and its rela-
tionship to psychosocial and CI. Participants with symptomatic AF 
were recruited and followed at 1 of 3 ambulatory clinics associated 
with the University of Massachusetts Medical Center AF Treatment 
Clinic (Heywood Hospital, Marlborough Hospital, and the University 
of Massachusetts Medical Center University Campus). The present 
analysis includes 218 InRhythm participants with symptomatic AF 
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and available clinical, psychosocial, cognitive, and QoL data. All 
participants gave informed consent, and all InRhythm protocols were 
approved by the University of Massachusetts Medical School Review 
Board.
Data Abstraction
All InRhythm study participants underwent a history, physical 
examination, and laboratory evaluation as part of their routine clinical 
evaluation for AF. The demographic, clinical, and treatment characteris-
tics of InRhythm participants were abstracted from the electronic medical 
record by trained study staff. Information abstracted from the medical 
record included information about participant’s age, sex, race, type of AF, 
cardiovascular comorbidities (eg, myocardial infarction, diabetes, hyper-
tension, and heart failure), noncardiovascular comorbidities (eg, anemia, 
renal failure), and prior antiarrhythmic drug exposure status. Participants 
were classified as having AF if the arrhythmia was present on a 12-lead 
electrocardiogram obtained during an AF Treatment Center clinic visit or 
an encounter with an outside health care provider, on a Holter or cardiac 
event monitor, or if AF was noted in any hospital record.
Cognitive Function
Global cognitive function was assessed using the Montreal 
Cognitive Assessment Battery (MoCA).17 The MoCA is a 10- minute, 
30-item screening tool that was designed to assist physicians in 
detecting mild CI. The MoCA is the currently recommended screen-
ing test for CI in patients with cardiovascular disease by the National 
Institute for Neurologic Disorders and Stroke and the Canadian 
Stroke Institute.18 A cutoff score of 27 (range, 0–30) has been shown 
to have a high sensitivity (0.90) and specificity (0.87) for detecting 
mild CI, and was used as a cutoff to define CI (scores of 26 and below 
were considered as “impaired”).17
Depression
Depression was assessed using the 9-item version of the 
Patient Health Questionnaire (PHQ-9).19 Using a cut-point range of 
≥10 (range, 0–27), the PHQ-9 has high sensitivity (0.88) and speci-
ficity (0.88) for detecting major depression.20
Anxiety
Anxiety was assessed using the Generalized Anxiety 
Disorder-7 scale, a revised version of the anxiety module from 
the PHQ that consists of Diagnostic and Statistical Manual of 
Mental Disorders, 4th Edition (DSM-IV) criteria for generalized 
anxiety disorder over the past 2 weeks.19 The Generalized Anxiety 
Disorder-7 scale score ranges from 0 to 27 with a score ≥10 having 
high sensitivity (0.89) and specificity (0.82) for psychiatrist-diag-
nosed anxiety disorder.21
Atrial Fibrillation-related Quality of Life
Disease-specific QoL was measured during a clinic visit 
using the Atrial Fibrillation Effect on QualiTy-of-Life (AFEQT) 
Questionnaire, which includes subscales for symptom severity, global 
well-being, AF burden, and impact on health care utilization.22 The 
AFEQT questionnaire consists of 20 questions separated into 4 
domains: symptoms, treatment concerns, daily activities, and treat-
ment satisfaction. Each question is graded on a 1- to 7-point scale, and 
the total raw score is transformed to a 0–100 scale, with 100 points 
indicating the best possible AF-related QoL and 0 points indicating 
the poorest possible AF-related QoL. AFEQT scores correlate to 
severity of physical symptoms from AF22 and health care utilization.23
Statistical Analyses
We compared the characteristics of InRhythm participants 
according to number of psychosocial and cognitive comorbidities 
(count of anxiety, depression, and CI; range, 0–3) and compared base-
line patient characteristics by number of comorbidities using analysis 
of variance for continuous variables and the χ2 test for categorical 
variables. We used a linear regression model to examine associations 
between baseline burden of psychosocial/cognitive comorbidity and 
AF-specific QoL score at 6 months, adjusting for all factors associ-
ated with psychosocial/cognitive comorbidity (P ≤ 0.2) in univariate 
analyses. Covariates included in multivariable models included age, 
sex, white race, education, smoking status, heart failure, prior stroke, 
anemia, renal failure, and total number of cardiac comorbidities.
RESULTS
A total of 218 adults with symptomatic AF who were willing 
to complete a study assessment of psychosocial factors and cogni-
tion comprised our study sample. The cohort was comprised mostly 
of middle-aged and older adults with a modest burden of cardiovascu-
lar and noncardiovascular risk factors. The cohort was predominantly 
female (64.9%) and white (93.9%) with an average age of 64 years. 
The majority of participants had paroxysmal AF (81%) and 68% had 
a college degree. Most patients carried a diagnosis of hypertension 
(77%) and the majority were taking an antiarrhythmic medication for 
rhythm control (82%). Just over one-half of participants used an anti-
platelet agent (56%) and 3 out of 4 were prescribed an oral anticoagu-
lation (56% on warfarin, 24% on a target-specific oral anticoagulant).
Burden of Psychosocial and Cognitive Comorbidities
Depression was the most commonly observed psychosocial 
or CI among InRhythm participants, noted in almost half of patients 
(45%). Nearly one-third (30%) of participants were cognitively 
impaired and 29% were noted to have anxiety (Fig. 1). Only 35% of 
FIGURE 1. InRhythm participants categorized by impairment 
in psychosocial and cognitive domains. Percentage values refer 
to the percent of the total study population (n = 218).
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participants were free from any psychosocial or CI. Psychosocial and 
cognitive comorbidities clustered frequently. Approximately one-third 
(34%) of the participants had a single psychosocial or CI, one-quarter 
(23%) had 2 impairments, and 7% were affected by all 3 impairments 
(Fig. 1).
Certain groupings of psychosocial/cognitive comorbidities 
were more common than others (Fig. 1). For example, almost one-
fifth (17%) of all participants experienced both depression and anxi-
ety. Anxiety more often co-occurred with depression and/or CI rather 
than in isolation. CI was most likely to occur on its own, but never-
theless almost half of participants with CI also had impairment in 
another domain (48%). Seven percent of participants were impaired 
in all 3 domains.
Patient Characteristics Associated With Increased 
Burden of Impairment
Participants with 1 or more psychosocial or CIs were older 
(P < 0.001), had less formal education (P < 0.001), and were more 
likely to be current smokers (P = 0.01). With the exception of heart 
failure, which was more prevalent among patients with multiple 
psychosocial and CIs (P = 0.03), the prevalence of comorbidities, 
such as hypertension, diabetes, stroke, etc., did not vary by level of 
psychosocial comorbidity (Table 1). Women were less likely than 
men to have multiple impairments (P = 0.02).
Baseline Burden of Psychosocial and Cognitive 
Impairment in Relation to AF-specific Quality of Life
Out of the 218 patients who completed baseline interviews, 
180 (82.5%) completed the AFEQT questionnaire 6 months after 
enrolment. Based on their responses, greater burden of psychosocial 
and CI at baseline was associated with poorer AF-specific QoL at 6 
months. In multivariable models adjusting for potential confounders 
(referent group = 0 impairments), there was a dose–response rela-
tionship between number of impairments and QoL score (Table 2). 
Impairment in 1 domain was associated with a 5-point (P = 0.236) 
lower score on the 100-point AFEQT, impairment in 2 domains with 
a 14-point (P < 0.001) lower score, and impairment in 3 domains was 
associated with a 15-point lower AFEQT score (P = 0.02).
DISCUSSION
In our study of 218 middle-aged and older adults with symp-
tomatic AF, we observed that anxiety, depression, and CI were 
common comorbid illnesses and frequently co-occurred. Certain 
patterns of psychosocial and cognitive comorbidity were noted, with 
TABLE 1. Characteristics of Participants by Burden of Psychosocial (Depression, Anxiety) or Cognitive Impairments
Characteristic
Number of Factors Impaired
P
0 1 2 3
N = 76 N = 75 N = 51 N = 16
Age, yrs, mean (SD) 65 (13) 70 (13) 75 (12) 77 (11) <0.001
Age, yrs, N (%)
  <65 31 (41) 26 (35) 9 (18) 2 (12)  
  65–74 23 (30) 16 (22) 12 (24) 3 (19)  
  75–84 17 (22) 23 (30) 19 (37) 7 (44)  
  ≥85 5 (7) 10 (13) 11 (21) 4 (25) <0.001
Female, N (%) 41 (54) 34 (46) 22 (44) 6 (35) 0.02
White race, N (%) 66 (87) 68 (91) 45 (88) 13 (82) 0.11
Education, N (%)
  <High school 7 (9) 12 (16) 17 (33) 7 (43)  
  High school/some college 24 (32) 33 (44) 19 (37) 6 (38)  
  ≥College graduate 46 (60) 30 (40) 15 (30) 3 (19) <0.001
  Current smoker, N (%) 8 (11) 13 (17) 4 (7) 2 (11) 0.01
Medical history, N (%)
  Heart failure 50 (66) 53 (70) 36 (71) 13 (81) 0.03
  Coronary artery disease 27 (36) 23 (30) 16 (32) 5 (30) 0.61
  Peripheral vascular disease 13 (17) 16 (21) 9 (17) 3 (21) 0.49
  Hypertension 60 (79) 58 (77) 42 (83) 13 (79) 0.44
  Diabetes 27 (36) 24 (32) 18 (36) 6 (38) 0.61
  Stroke 6 (8) 8 (10) 8 (16) 3 (19) 0.15
  Alcohol abuse/dependency 5 (7) 2 (3) 3 (6) 1 (8) 0.69
  Anemia 14 (18) 14 (18) 13 (25) 3 (19) 0.18
  Asthma/COPD 17 (23) 27 (36) 14 (28) 5 (31) 0.06
  Renal failure 21 (27) 26 (34) 19 (38) 6 (39) 0.11
  Implantable cardiac device 10 (13) 6 (8) 6 (12) 2 (15) 0.25
  Total cardiac comorbid conditions, 
mean (SD)*
3.4 (1.5) 3.4 (1.6) 3.6 (1.5) 3.7 (1.6) 0.06
*Cardiac comorbidities include heart failure, coronary artery disease, hypertension, diabetes, stroke, and peripheral vascular disease.
COPD indicates chronic obstructive pulmonary disease.
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anxiety and depression frequently being observed together. Finally, 
we showed that impairment in 2 or more cognitive or psychosocial 
domains was associated with lower AF-specific QoL at 6 months in 
adjusted regression models.
Depression or anxiety have been shown to affect up to one-
half of patients with AF,6 and patients with AF are at a 2-fold higher 
risk of CI than same-aged patients without AF.24 Thus, the rates of 
anxiety, depression, and CI observed in our study were high, but 
remarkably similar to those reported in prior, albeit smaller studies 
of patients with AF.6,25 The current study validates these findings in a 
larger sample of well-characterized ambulatory patients with symp-
tomatic AF and extends current knowledge by illustrating that these 
psychosocial and/or CIs frequently co-occurred in individual patients 
(Fig. 1). Furthermore, impairment in multiple domains was associ-
ated with poorer AF-specific QoL at 6 months.
Importantly, we observed that psychosocial and cognitive mul-
timorbidity exerts a powerful and negative effect on AF-specific QoL. 
Differences in QoL scores between participants with multiple impair-
ments as compared with participants with CI, anxiety, and depression 
alone were clinically meaningful26 and statistically significant. Our 
finding that AF patients with an increasing burden of psychosocial or 
cognitive comorbidities also reported that lower QoL scores reflects 
greater symptom severity and likely relates to the fact that depressed 
and anxious AF patients utilize health resources at higher rates than 
do patients free from these mood disorders (eg, greater number of 
clinic and emergency room visits).6,9 Indeed, several previous stud-
ies have examined the negative impact of individual psychosocial 
impairments on QoL in patients with AF.6,9,27 However, only one of 
these prior studies assessed AF-specific QoL,9 and none examined 
how the co-occurrence of multiple impairments collectively affected 
AF-specific QoL.
As mentioned above, depression, anxiety, and CI are common 
in patients with AF6,24; they are also common in other chronic car-
diovascular pathologies. As illustrated by the 2008 statement of the 
American Heart Association’s Council on Clinical Cardiology, mood 
and cognition are becoming increasingly recognized for their role 
in the risk, management, and prognosis of cardiovascular disease, 
including in the context of stable coronary artery disease, heart fail-
ure, AF, and myocardial infarction.28–32 Impairments in mood and 
cognition have myriad adverse effects, including higher rates of mor-
bidity, symptom severity, health care utilization, and even mortality.30
Although there is a growing appreciation for the importance 
of mood and CIs in the natural history of AF, no prior studies have 
examined their co-occurrence in AF patients. Especially in light of 
the fact that anxiety and depression so frequently co-occur in indi-
viduals with other chronic medical conditions,33 and given their 
negative effects on cognitive performance,13 it is not surprising, but 
nonetheless significant, that we observed a high rate of multimor-
bidity across distinct psychosocial and cognitive domains in patients 
with symptomatic AF. Our findings point to the profound impact of 
disease clusters on symptom severity, suggesting that assessments of 
mood and cognition should be performed in concert to best charac-
terize AF patients at the greatest risk for complications.
Despite the increasing recognition of the importance of cogni-
tive and psychosocial characteristics as determinants of response to 
cardiovascular treatments, including rhythm control for AF, contem-
porary AF Treatment Guidelines do not recommend routine assess-
ment for CI, depression, or anxiety.34 Our findings would suggest 
that such assessments might be useful in patients with symptomatic 
AF given their close relations with AF-specific QoL, symptom bur-
den, and rehospitalization, which are major targets for contemporary 
rhythm control therapies, especially catheter ablation.35
Strengths and Limitations
The strengths of the present investigation include its prospec-
tive design, the enrollment of AF patients recruited from 3 different 
academic and community ambulatory clinics, the indepth character-
ization of participants’ AF history, as well as the use of validated 
instruments to characterize each participant’s psychosocial status, 
cognitive function, and QoL. Our study has several limitations, 
however, that should be considered when interpreting our results. 
First, all InRhythm study participants had symptomatic AF and were 
identified from cardiology clinics, so our findings may not be gen-
eralizable to older asymptomatic AF patients1 who are evaluated 
in other settings. Also, the InRhythm cohort was comprised mostly 
of white individuals of European descent and those with paroxys-
mal AF, thereby limiting generalizability of our primary findings to 
other racial and ethnic groups or those with different types of AF. 
Finally, we did not adjust for factors that may have confounded or 
mediated relations between psychosocial and cognitive predictors 
and AF-specific QoL (eg, adherence to medications, cardioversions, 
emergency department visits, or baseline symptom severity).
CONCLUSIONS
Our findings suggest that cognitive and psychosocial impair-
ments are common among patients with symptomatic AF and often 
co-occur, imparting risk for poorer AF-specific QoL. Knowledge of 
psychosocial and CIs may help guide patients, families, and physi-
cians in appropriate screening and making informed AF treatment 
decisions.
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